Cardiovascular disease remains a leading cause of mortality worldwide, and much of its burden could be reduced by detecting risk earlier. High-sensitivity cardiac biomarkers are central to that goal: the lower and more precisely we can measure them, the sooner subtle changes can be recognised.
The biomarkers that matter
- High-sensitivity cardiac troponin (hs-cTn): the cornerstone marker for myocardial injury; lower detection limits enable earlier and more confident assessment.
- BNP / NT-proBNP: indicators of cardiac stress and heart-failure risk.
- Emerging markers: a growing panel associated with inflammation, fibrosis and early cardiac remodelling.
Why going lower changes the picture
For cardiac markers, sensitivity is not a cosmetic improvement — it is clinically meaningful. Detecting troponin at very low concentrations helps distinguish genuine signal from noise in the critical early window, and tracking small longitudinal changes can reveal risk before an event occurs. Achieving this reliably calls for assays that reach into the femtogram range while maintaining a broad dynamic range.
Mecwins' AVAC technology is built precisely for that challenge. By counting individual plasmonic-nanoparticle-labelled targets through dark-field micro-spectrophotometry, the AVAC Analyzer combines ultra-high sensitivity with a simple, robust workflow — a combination well suited to cardiovascular biomarker research.
Toward earlier, more predictive cardiology
The direction of travel in cardiac diagnostics is clear: earlier detection, better risk stratification, and more personalised follow-up. Ultrasensitive measurement of established and emerging markers is a key enabler of that future.
To explore ultrasensitive cardiac biomarker detection for your research, contact the Mecwins team.